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Abstract
Renal ischemia/reperfusion injury (IRI) frequently complicates shock, renal transplantation and cardiac and aortic surgery,
and has prognostic significance. The translocation of phosphatidylserines to cell surfaces is an important pro-inflammatory
signal for cell-stress after IRI. We hypothesized that shielding of exposed phosphatidylserines by the annexin A5 (ANXA5)
homodimer Diannexin protects against renal IRI. Protective effects of Diannexin on the kidney were studied in a mouse
model of mild renal IRI. Diannexin treatment before renal IRI decreased proximal tubule damage and leukocyte influx,
decreased transcription and expression of renal injury markers Neutrophil Gelatinase Associated Lipocalin and Kidney Injury
Molecule-1 and improved renal function. A mouse model of ischemic hind limb exercise was used to assess Diannexin
biodistribution and targeting. When comparing its biodistribution and elimination to ANXA5, Diannexin was found to have
a distinct distribution pattern and longer blood half-life. Diannexin targeted specifically to the ischemic muscle and its
affinity exceeded that of ANXA5. Targeting of both proteins was inhibited by pre-treatment with unlabeled ANXA5,
suggesting that Diannexin targets specifically to ischemic tissues via phosphatidylserine-binding. This study emphasizes the
importance of phosphatidylserine translocation in the pathophysiology of IRI. We show for the first time that Diannexin
protects against renal IRI, making it a promising therapeutic tool to prevent IRI in a clinical setting. Our results indicate that
Diannexin is a potential new imaging agent for the study of phosphatidylserine-exposing organs in vivo.
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Introduction
Ischemia/reperfusion injury (IRI) is a major cause of cardio-
vascular morbidity and mortality [1]. Most sensitive to IRI are
organs with a high energy demand and an intricate mircovascular
network, such as the kidney. Renal IRI frequently complicates
shock, cardiac and aortic surgery, delays graft function after
transplantation, and has prognostic significance [2,3]. Further-
more, renal IRI is a major cause of acute kidney injury (AKI), and
is commonly observed in e.g. renal artery stenosis, sepsis, and
various types of renal surgery [4,5]. Even though IRI is an
important and common clinical problem, effective strategies to
reduce this condition are inadequate and novel therapies are
needed.
The characteristic pathologic changes associated with IRI
induced AKI are classically believed to be acute tubular necrosis
and interstitial inflammatory cell infiltration [6,7]. In addition, the
role of microvascular dysfunction in AKI has generated increasing
interest [8]. The persistence of decreased blood flow after
reperfusion (the ‘no-reflow’ phenomenon) is thought to play an
essential role in AKI development, especially in the corticomed-
ullary junction and outer medulla. The activation of endothelial
cells in microcirculatory vessels is an important event in the
inflammatory response upon IRI. Particularly, the translocation of
phosphatidylserines (PS) to the outer leaflet of the endothelial cell
plasma membrane appears to play a central role in the cascades
leading to end-organ damage [9,10].
Exposed on the endothelial cell surface, PS serve as a binding
site for leukocytes, which are able to specifically recognize this
phospholipid through a putative PS-receptor or via bridging
molecules [11,12]. Furthermore, PS exposition contributes to pro-
thrombinase complex formation and is an important trigger of the
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complement cascade [13,14]. As a result, platelets and leukocytes
will bind to the activated endothelium and cause an extended pro-
thrombotic and pro-inflammatory response, consisting of T-cell
recruitment and infiltration of monocytes and macrophages
[8,15]. Overall, adhesion of immune cells will reduce blood flow
in the renal microcirculation and cause capillary plugging, thereby
aggravating the ischemic injury to renal tubule cells [7].
In light of the detrimental effects of PS exposition, we
hypothesize that shielding of PS by PS-binding proteins will
inhibit their pro-inflammatory effects, thereby reducing IRI. The
endogenous protein annexin A5 (ANXA5) binds with nanomolar
affinity to PS in a calcium-dependent manner [16,17]. ANXA5
forms a 2D crystal structure on PS exposing cell membranes in
vitro, thereby shielding PS from the extra-cellular environment
[18]. For endothelial cells, shielding of PS by ANXA5 was shown
to have both anti-thrombotic effects [19], and to prevent
leukocytes adhesion [20], making this protein a promising
candidate to reduce microvascular dysfunction after IRI. Howev-
er, rapid renal clearance of ANXA5 limits its clinical utility. In
contrast, the synthetic ANXA5 homodimer Diannexin (DA5) was
recently claimed to have an increased half-life in the circulation in
vivo as well as high affinity for exposed PS in vitro [21].
The aim of the present study was to investigate the protective
role of DA5 in the kidney. We demonstrate for the first time that
DA5 ameliorates renal function after IRI, reduces leukocyte influx
and tubular damage and reduces renal injury marker expression.
Secondly, we determined the short-term biodistribution of DA5
and show for the first time that DA5 targets specifically to tissues
undergoing I/R, via high-affinity binding to exposed PS. We
conclude that DA5 is a promising candidate to prevent renal IRI,
and that these effects are likely mediated through PS-shielding.
Results
DA5 reduces tubule damage and leukocyte influx after
renal IRI and improves renal function
We investigated the effects of DA5 pretreatment on ischemic
kidney damage in a mouse model of bilateral renal IRI. We
applied a mild IRI stimulus by inducing 20 min of renal ischemia
and either 3 or 8 days of reperfusion. Subsequently, we assessed
renal damage, local inflammation and kidney function in mice
treated with DA5 or vehicle in comparison to sham-operated
mice.
Renal proximal tubule damage was quantified by scoring of
histological sections (Figure 1). Sham-operated mice lacked any
signs of tubular damage and scored 060 points. Proximal tubule
damage was significantly increased in vehicle-treated mice on day
3 and day 8 post-I/R (P,0.001 and P,0.01, respectively). Damage
scores of kidneys from DA5-treated mice did not differ from sham-
operated mice on day 3 or day 8. Moreover, DA5 significantly
reduced proximal tubule damage on day 3 when compared to
vehicle-treated mice (P,0.05). Granulocyte influx in the renal
cortex was quantified by granulocyte counting in histological
sections (Figure 2). On day 3 post-I/R, granulocyte influx in the
renal cortex of vehicle-treated mice was significantly higher than
in DA5-treated mice (P,0.01).
We measured protein and mRNA levels of KIM-1 and NGAL,
two established biomarkers for renal damage [22,23]. Western blot
analysis showed that KIM-1 and NGAL protein expression was
elevated 3 days after I/R in both treatment groups, when
compared to sham-operated mice. On day 3, DA5 treatment
reduced the I/R-induced KIM-1 and NGAL protein expression
by ,50%, when compared to vehicle-treated mice (P,0.001;
Figure 3B-C). After 8 days of reperfusion, the increase in KIM-1
protein expression persisted in both treatment groups, but was
,35% lower in DA5-treated animals (P,0.05). NGAL protein
expression on day 8 did not differ between treatment groups, but
was increased above sham-levels only in DA5-treated mice. In line
with the protein levels, KIM-1 mRNA levels were increased in
vehicle-treated groups on day 3 and day 8 post-ischemia (P,0.001
and P,0.05, respectively; Figure 3D). In DA5-treated animals,
mRNA levels did not differ from sham-operated animals on day 3
or day 8, while KIM-1 mRNA expression on day 3 was
significantly lower than in vehicle-treated mice (P,0.05). For
NGAL, no significant increase in mRNA expression could be
detected (Figure 3E), probably because this marker reached its
maximum transcription at an earlier time-point [22].
On the functional level, renal damage in mice undergoing I/R
was reflected by a significant increase in plasma urea (sham
10.861.7 vs. vehicle-treated 17.968.0 mmol/l), renal glucosuria
and an increase in urine flow (Figure 4) on day 3 post-op, when
compared to sham-operated mice. Plasma glucose did not differ
between sham-operated mice (10.061.0 mM) and vehicle- or
DA5-treated mice (8.961.9 and 11.465.1 mM, respectively).
Recovery of renal function was observed on day 8, when plasma
urea (sham 10.861.7 vs. vehicle-treated 13.765.8 mmol/l), urine
glucose and urine flow (Figure 4) returned to baseline levels. DA5
treatment had beneficial effects on tubular function on day 3 after
IRI: glucosuria was reduced when compared to vehicle-treated
mice (P,0.001; Figure 4A). DA5 also prevented the increase in
urine flow observed in vehicle-treated mice 3 days after I/R-
induction (P,0.05; Figure 4B). Water intake after surgery was not
different from baseline (3.860.7 ml) for either DA5 or vehicle
treated animals (2.461.5 and 3.261.6 ml, respectively, P.0.05).
No effect of DA5 on plasma urea was observed.
Biodistribution and elimination of ANXA5 and DA5 after
i.v. administration
We compared the biodistribution and elimination of DA5 with
monomer ANXA5, in order to clarify the pharmacokinetic
properties and imaging potential of DA5. Both proteins were
labelled with Technetium-99m (99mTc) via hydrazinonicotinamide
(HYNIC) conjugation.
Ten min after i.v. injection, blood levels of 99mTc-ANXA5 were
measured at 6.5% 6 0.8 of the injected dose per gram (%ID/g;
Figure 5A). This level decreased rapidly over the next 20 min to
2%ID/g, and declined further during the remaining 90 min. In
line with previous reports, we found that 99mTc-ANXA5
accumulation was most pronounced and rapid in the kidney
(Figure 5B and Figure S1A). 99mTc-ANXA5 accumulation in liver
and spleen was slow and did not exceed 6 %ID/g. Tracer
concentration in intestine, lung and heart was below 2%ID/g after
two h. For 99mTc-DA5 (Figure 5C), blood levels after 10 min were
.3 times higher than those of 99mTc-ANXA5 (24.563.4%ID/g
vs. 6.560.8%ID/g; P,0.01) and declined to just below 3%ID/g
after 1 hour. Accumulation of 99mTc-DA5 was prominent in
kidney, liver and spleen (Figure 5D and Figure S1B), suggesting
that ANXA5 and DA5 have different routes of elimination and/or
metabolism. Uptake in heart and lung tissue was ,10%ID/g after
10 min, but decreased in chorus with declining blood levels,
suggesting that the 99mTc-DA5 content of these tissues was
dependent on the concentration in the blood.
DA5 targets ischemic tissues after hind limb IRI
Since previously published data emphasize the high affinity of
DA5 for exposed PS [21], we investigated whether DA5 targets to
ischemic tissues and tested if DA5 and ANXA5 share similar
binding sites, reflecting specific targeting to PS. Targeting of both
Diannexin Protects against Renal I/R-Injury
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99mTc-ANXA5 and 99mTc-DA5 was investigated in an ischemic
exercise model of the mouse hind limb, mimicking our
experimental set up used to detect ANXA5 targeting after
ischemic exercise in humans in vivo [10]. We injected the
radiolabeled annexin analogues immediately prior to reperfusion
and measured the targeting of 99mTc-ANXA5 and 99mTc-DA5
during 2 h of reperfusion. Muscle tissue from the untreated
contralateral limb served as negative control. 99mTc-ANXA5
targeting to the muscle subjected to I/R was significantly elevated
at all measured time points (Figure 6A). This targeting appeared to
decrease during the first 30 min of reperfusion, which may be due
to reactive hyperaemia and decreasing blood levels of 99mTc-
ANXA5 (Figure S1A). However, targeting reached a steady-state
between 30 and 120 min, indicating high affinity binding of
99mTc-ANXA5 in muscle tissue after I/R. For 99mTc-DA5,
targeting to the I/R muscle increased over time, reaching a
maximum after 60 min of reperfusion (Figure 6B). Thus, 99mTc-
DA5 targeting appeared to accumulate over time, even though
99mTc-DA5 blood levels decreased. Furthermore, targeting of
99mTc-DA5 was significantly higher than that of 99mTc-ANXA5
after 1 h (1.560.3%ID/g vs. 3.760.7%ID/g; P,0.05) and 2 h
(1.660.3%ID/g vs. 2.960.6%ID/g; P,0.05).
In a second set of experiments, we showed that targeting of both
99mTc-ANXA5 and 99mTc-DA5 to the ischemic muscle was
Figure 1. Diannexin (DA5) reduces proximal tubule damage after ischemia-reperfusion injury. (A–D) Representative images of PAS-
stained kidney sections (magnification 100x), showing 4 levels of proximal tubule damage after I/R. (A) Damage score 0: intact brush borders and
absence of casts or destroyed tubules. Damage score 1 (image not shown) was given for scattered cast formation in less than 1% of tubules. (B)
Damage score 2: often clustered cast formation in 5–25% of the tubules. (C) Cast formation and destroyed tubules affecting 40–60% of tubules. (D)
Damage score 4: Extensive destruction and cast formation in 70–90% of tubules. Damage score 5 (not observed): destruction or cast formation in
100% of tubules. (E) When compared to sham-operated mice, renal cortex damage was significantly increased in vehicle-treated groups on day 3 and
day 8 post-I/R. Damage in the DA5-treated groups did not differ significantly from sham-operated mice on day 3 or day 8 post-I/R. On day 3, DA5
treatment significantly reduced renal damage when compared to vehicle-treated mice. Values are means6 SEM. *P,0.01, **P,0.001 vs. sham group;
#P,0.05 vs. ctrl group. n = 5 for sham-operated mice and n=10 for all other groups.
doi:10.1371/journal.pone.0024276.g001
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blocked by administering 450 mg of unlabelled monomer ANXA5
prior to ischemia and the injection of labelled substrate (Figure 6C,
D). This finding confirms our hypothesis that ANXA5 and DA5
have the same binding sites, reflecting specific targeting to PS.
Discussion
The present study is the first to demonstrate that the ANXA5
homodimer DA5 decreases renal damage after IRI, in terms of
kidney morphology, inflammation, gene expression and renal
proximal tubule function. Furthermore, we show that DA5 targets
specifically to exposed PS in ischemic tissue in vivo.
The therapeutic effects of DA5 have been studied previously in
rodent models of hepatic and pancreatic IRI and transplantation
[24–26], and in an IRI model of rat cremaster muscle [27].
However, favourable effects on renal IRI were not yet demon-
strated, even though its vulnerability to I/R and its impact on
prognosis make the kidney an ideal candidate for preventive
treatment against IRI. Clinical conditions that jeopardize renal
perfusion are frequently encountered and can often be predicted,
e.g. in elective major surgery and kidney transplantation. In such
cases, an intervention that should preferably be timed at the
moment of I/R is practical. Here, we used a murine model of
renal IRI to show that a single i.v. administration of DA5 (200 mg/
kg b.w.) 15 min before renal IRI decreases proximal tubule
damage, nearly abolishes leukocyte influx, decreases transcription
and expression of renal injury markers and ameliorates renal
function. These effects were observed after 3, and up to 8 days of
reperfusion, indicating that the beneficial effect of DA5 outlasts the
acute phase of I/R and lasts for several days.
We observed beneficial effects of DA5 on renal morphology,
leukocyte influx, as well as functional changes in urine flow and
urine glucose. There is increasing evidence that PS externalisation
on the endothelial cell membrane is an early event in IRI, giving
rise to the adhesion and aggregation of activated leukocytes and
platelets in the microcirculation. This in turn exacerbates injury
due to e.g. ROS formation, the release of proteolytic enzymes from
adherent or transmigrated leukocytes, and diminished microcir-
culatory perfusion. Our findings show that DA5 is able to shield
exposed PS, and that leukocyte influx into the ischemic kidney is
reduced in DA5-treated mice. Similar to monomeric ANXA5, the
anti-inflammatory and anti-thrombotic properties of DA5 are
thought to originate from its ability to shield PS, thereby reducing
leukocyte adherence and transmigration, as well as preventing the
formation of the pro-thrombinase complex. Prevention of
leukocyte and platelet adhesion in turn leads to improved
microcirculation, while reduced leukocyte infiltration diminishes
the secondary inflammatory response. The precise mechanism of
action is currently unknown; similar to ANXA5, DA5 may alter
the accessibility and/or membrane expression of adhesion
molecules through steric hindrance, and/or influence endocytosis
and phagocytosis. For ANXA5, these effects are contributed to PS-
binding and subsequent 2D crystallisation of the protein on PS-
exposing membranes. It is at present unknown whether DA5
exhibits 2D-crystallization. Lastly, we cannot exclude that the anti-
inflammatory effects of DA5 could be receptor-mediated, or based
on intracellular actions of the protein. As was recently described
for annexin A1, receptor activation on the epithelial cells and/or
leukocytes can greatly reduce leukocyte adhesion and infiltration
[28]. Such a receptor for ANXA5 is putative at best, although
ANXA5 has been shown to be internalised by living cells [29] and
influence PKC activity. For DA5 it is at present unknown whether
these processes occur and therefore, full understanding of the
mechanism requires further investigation.
Apart from the morphological and functional outcome
measures mentioned above, we also assessed the renal damage
markers KIM-1 and NGAL in our mouse model. The great
advantage of these markers is that they are early, sensitive,
diagnostic indicators of kidney injury when compared to
conventional biomarkers, e.g. plasma creatinine and blood urea
nitrogen [23,22]. Moreover, in mice these markers are preferred
over creatinine clearance (CCr), since the impact of tubular
creatinine excretion on CCr is even larger in mice than in humans,
raising questions regarding the reliability of creatinine for
measuring renal function in these animals [30]. Furthermore,
these markers support our measurements of urine flow and urine
glucose, which are important, although not standard, indicators of
(proximal) tubule damage, since glucosuria indicates proximal
tubular dysfunction, but does not directly reflect a change in GFR.
We show here that KIM-1 and NGAL are expressed at low levels
in healthy renal tissue, but increase dramatically in the post-
ischemic kidney. DA5 treatment reduced the expression and
transcription of KIM-1 after 3 and 8 days of reperfusion. It has
been shown in vivo that the ectodomain of KIM-1 is shed into the
urine in rodents and humans after proximal tubular kidney injury.
This provides us with an important tool for future research to
translate current findings to humans in vivo. We found no
significant increase in NGAL mRNA expression, but this marker
has been reported to reach its maximum transcription at an earlier
time-point [22]. Decreased levels of KIM-1 and NGAL mRNA
were also observed in a pilot study of unilateral renal IRI, in which
DA5 was administered directly upon reperfusion, rather than 15
minutes before ischemia (unpublished observations; Wever et al.
2009). Interestingly, KIM-1 has been described as a PS receptor
involved in the conversion of epithelial cells to semi-professional
phagocytes [31]. Thus, KIM-1 may actually play a mechanistic
role in kidney injury downstream of the initial PS exposure.
Shielding of PS by DA5 could therefore lead to a decrease in
KIM-1-mediated phagocyte recruitment, thereby reducing dam-
age.
Figure 2. Diannexin (DA5) reduces leukocyte influx 3 days after
I/R. Representative pictures of leukocyte influx in (A) vehicle-treated
mice and (B) DA5-treated mice (magnification 400x). Granulocytes
stained with Leder’s esterase are indicated with arrowheads. (C) When
compared to vehicle-treated mice, leukocyte influx in renal tissue of
DA5-treated mice was decreased on day 3 after IRI induction. Values are
means 6 SEM. **P,0.01 vs. vehicle. n = 8–10 mice per treatment.
doi:10.1371/journal.pone.0024276.g002
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In addition to our therapeutic findings, this study is the first to
show comparative data on the biodistribution and elimination of
ANXA5 and DA5. These data are of vital importance for future
clinical studies, since the pharmacokinetic and imaging properties
of DA5 are largely dependent on these parameters. In cardiovas-
cular medicine and oncology, detection of apoptosis, which is
accompanied by PS exposure, may provide important diagnostic
and therapeutic information. Previous reports on the biodistribu-
Figure 3. Diannexin (DA5) reduces expression and transcription of renal injury markers after IRI. (A) Representative western blot of
kidney homogenate from DA5 and vehicle-treated mice (ctrl), after 3 or 7 days of reperfusion, stained for KIM-1, NGAL and b-actin. Purified KIM-1 and
NGAL protein were used as positive control. (B,C,D) When compared to sham operation, KIM-1 and NGAL expression, as well as KIM-1 transcription,
were increased in renal tissue 3 and 8 days after IRI induction. DA5 treatment significantly reduced protein expression on day 3 (KIM-1 and NGAL) and
day 8 (KIM-1), when compared to vehicle-treated mice (ctrl). Also, DA5 reduced the IRI-induced transcription of KIM-1 on day 3 and day 8. (E) NGAL
mRNA expression was not significantly elevated on day 3 or day 8 post-IRI. CT-values for corresponding b-actin were 17.263.2 for KIM-1 and 18.562.9
for NGAL. Values are means6 SEM. *P,0.05, **P,0.001 vs. sham group; #P,0.05, ##P,0.001 vs. ctrl group. n = 5 for sham operated mice and n= 10
for all other groups.
doi:10.1371/journal.pone.0024276.g003
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tion and clearance of 99mTc-HYNIC-ANXA5 in humans and
rodents showed rapid accumulation of ANXA5 in kidney (,50%
of the injected dose; ID) and liver (,12%ID) after 1–3 h.
Furthermore, kinetic data for ANXA5 in the human circulation
indicate a short plasma half-life of 24 min, while clearance
occurred almost exclusively via urinary excretion [32,33].
Clearance of DA5 has been studied previously in rats using a
125I-DA5-conjugate. DA5 clearance fitted a two-compartment
model, revealing a 1st and 2nd phase half life of ,12 min and
,6.5 h, respectively [24]. In the present study, we evaluated the
99mTc-DA5 pharmacokinetics together with 99mTc-ANXA5, and
confirmed the longer half-life of 99mTc-DA5 as compared to
99mTc-ANXA5. For imaging purposes, generally a short half-life is
preferred, because this allows rapid clearance of the tracer from
the background. However, the circulatory half-life is also the
driving force for accumulation of the tracer in the target tissue.
The circulatory half-life of Annexin A5 is considered to be too
short for many imaging purposes, as discussed in e.g. [34,35]. The
slightly longer half-life of DA5, combined with its higher affinity
for PS, makes the dimer more suited to image PS exposure in
tissues in vivo than monomer ANXA5. We found that 99mTc-DA5
shows physiologic uptake in liver, spleen and kidney. With respect
to the imaging properties of DA5, this nonspecific uptake in
abdominal organs may hamper visualization of apoptosis in tissues
in the vicinity of these organs, although in most cases single photon
emission computed tomography (SPECT) imaging will allow
distinction between physiologic uptake and uptake in tissues
nearby. Biodistribution studies using various DA5 conjugate/
radionuclide combinations are required to optimize the imaging
potential of DA5 [36].
In our experiments on DA5 and ANXA5 targeting, we found
that 99mTc-DA5 accumulates in the hind limb muscle during the
first 2 h after ischemic exercise. Targeting of DA5 increased over
time and was significantly higher than that of ANXA5, which
translates previous in vitro observations stating that DA5 has a
higher affinity for PS than ANXA5 [21], to the in vivo setting.
Furthermore, we showed that 99mTc-DA5 targeting to ischemic
tissues is PS-specific, since its binding was inhibited by unlabeled
ANXA5. This observation indicates that DA5 and ANXA5 share
the same binding sites in the ischemically exercised muscle and it is
well appreciated that ANXA5 specifically binds to PS [37,16].
The importance of exposed PS in ischemic injury is grounded
by our evidence that PS-targeting by DA5 attenuates IRI in the
kidney. The therapeutic effects of DA5, such as those shown in our
renal IRI model, are thought to be local rather than systemic and
may be enhanced by DA5 enrichment in ischemic tissues. The
higher in vivo affinity of DA5 for PS likely results in a higher
efficacy of this drug to prevent IRI as compared to ANXA5. The
therapeutic dose and maximal tolerable dose of DA5 in humans
have not yet been determined, but DA5 administration in patients
in single doses up to 400 mg/kg was reported to be without serious
complications [27]. Hemorrhagic complications in particular
could, theoretically, be of concern. Of note, DA5 administration
did not induce any notable post-operative bleeding complications
in any of our mice (observations in .60 mice, data not shown).
Overall, effects of ANXA5 and DA5 on systemic haemostasis have
been reported to be very minimal [21,19,24]. It is likely that
reduced inflammation, by diminished leukocyte adhesion, and
consequently reduced tissue damage are involved in protection by
DA5. This makes DA5 a promising new therapeutic agent to
prevent IRI in a wide range of clinical settings where renal
perfusion is at risk. Furthermore, DA5 may offer new possibilities
in the field of PS-imaging in e.g. atherosclerosis, and used to
provide valuable insights in the pathogenesis of the disease. As a
first step towards clinical studies on DA5, the homodimer has
recently completed a Phase II clinical trial in kidney transplan-
tation [26].
Materials and Methods
Chemicals
DA5 was an unrestricted gift from Alavita Pharmaceuticals Inc.
(Mountain View, CA). ANXA5 was obtained from Theseus
Imaging (Boston, MA). SYBR GreenH and TaqmanH Universal
PCR Master Mix and NGAL and b-actin primer probe sets
(Mm01324470_a1 and 4352933E) were from Applied Biosystems,
Zwijndrecht, The Netherlands.
Animals
All procedures involving animals were approved by the
Committee for Animal Experiments of the Radboud University
Nijmegen Medical Centre (experiment ID’s DEC2008121 and
DEC2009006). Male FVB (Friend leukaemia virus B strain) mice
were obtained from Charles River Germany at 5–7 weeks of age,
weighing 18–22 grams on arrival. Animals were housed under
standard specific pathogen free housing conditions at the Central
Animal Facility Nijmegen. Up to 10 mice per cage were housed
in Macrolon cages (Techniplast, Buguggiatta, Italy), supplied with
woody bedding, shelters and treadmills. Mice had ad libitum access
to drinking water and standard chow (RMH-TM, Hope Farms,
Figure 4. Diannexin (DA5) improves kidney function after renal
IRI. Urine flow and urine glucose were measured at baseline, and 3 and
8 days after renal IRI. Twenty minutes of renal IRI significantly increased
both parameters when compared to sham-operated mice on day 3. On
day 8, recovery of renal function was observed. (A) When compared to
vehicle-treated mice (ctrl), DA5-treatment reduced glucosuria on day 3.
(B) Urine flow was increased on day 3 post-ischemia in vehicle-treated
controls, which was normalized by DA5 treatment. Values are means 6
SEM. *P,0.05, **P,0.01 vs. sham; #P,0.05, ##P,0.001 vs. DA5 group.
n = 5 for sham operated mice and n=10 for all other groups.
doi:10.1371/journal.pone.0024276.g004
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Woerden, The Netherlands). The environmental temperature
was regulated at 22uC, with a relative humidity of 6 45% and a
12/12 h day/night cycle in artificial lighting with white lights on
at 06:00 h. Radio sound was played during the day period. Air
was refreshed at the rate of approximately six times per hour.
Mice were allowed to acclimatize for at least one week before
surgery.
Metabolic cages
Single mouse metabolic cages (Techniplast, Buguggiate, Italy)
were used to assess renal function 7 days pre-op and 2 or 7 days
post-op. Prior to 24 h housing in metabolic cages, mice were
weighted and 0.5 ml physiological salt solution was administered
s.c. to prevent dehydration. To prevent hypothermia, room
temperature was raised to 24uC with a relative humidity of 53–
68%. After 24 h, body weights (b.w.) were recorded and a blood
sample was collected via the retro-orbital sinus under isoflurane
anaesthesia (5% in O2/N2O).
Surgical procedures
All experiments were performed between 08.00 and 16.00 h.
Surgical procedures were conducted using standard aseptic
surgical techniques and all microsurgical instruments were
sterilized using a dry bead sterilizer (Inothech, Dottikon,
Switzerland). Animals were placed on a sterile drape overlying a
heating pad to maintain body temperature at 37uC, which was
monitored continuously using a rectal thermometer probe. Body
weights were recorded prior to surgery. Anaesthesia was induced
with 5% isoflurane in O2/N2O and maintained at 2.5–3%. Depth
of anaesthesia was assessed by toe and tail pinch.
DA5 and ANXA5 biodistribution and elimination
99mTc-DA5 and 99mTc-ANXA5 were prepared as described
previously [10] at a specific activity of 5–25 mCi/mg. The
radiolabelled products were purified by PD-10 column. The
radiochemical purity was found to be .90%, as determined by
instant thinlayer chromatography. PS-binding of the 99mTc-DA5
and 99mTc-ANXA5 conjugates was confirmed using denaturated
erythrocytes in vitro as described previously [38].
Mice were anaesthetised and 200 mg/kg b.w. of 99mTc-DA5 or
99mTc-ANXA5 was administered i.v. via the tail vein. For
scintigraphic imaging of whole body 99mTc biodistribution at 0,
10, 30, 60 and 120 min, mice (n = 3 per treatment) were placed on
the low-energy collimator of a single-headed gamma camera
(Orbitor, Siemens, Hoffman Estates IL). Animals were re-
anaesthetized for measurements at 30, 60 and 120 min, after
which they were euthanized through exsanguination. The 99mTc
content of blood and various tissues was determined by counting
tissue samples in a well-type gamma counter (Wizard, Pharmacia-
LKB).
Figure 5. Biodistribution of Annexin A5 (ANXA5) and Diannexin (DA5) after i.v. injection, over a time course of 2 h. Uptake of 99mTc in
vital organs is presented as % of the injected dose (ID) per gram. (A) Plasma levels of ANXA5 declined steeply 10 to 30 min after injection. (B)
Accumulation was most pronounced and rapid in the kidney, while low levels of ANXA5 were found in liver and spleen. (C) DA5 blood levels at
t = 10 min were over 3 times higher than of ANXA5 and declined until 1 h after injection. (D) Accumulation of the probe was detected in kidney, liver
and spleen. Values are means 6 SEM. n= 3 mice per treatment.
doi:10.1371/journal.pone.0024276.g005
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Hind limb ischemic exercise model
Anaesthesia was induced and mice (n = 3–4 for 10, 30 and
120 min reperfusion and n= 7–8 for 60 min reperfusion)
remained anesthetized until sacrifice. The Nervus ischiadicus of the
right hind limb was exposed via an incision and blunt dissection
through the right thigh. A 1 mm silicone copper wire, with a
stripped section of 2–3 mm at 2 cm from its tip, served as positive
electrode. The stripped section was placed underneath the nerve
and the wire was tunnelled s.c. to exit at the tail base. A second
length of wire with stripped ends was used as negative electrode,
inserted through the heel of the right hind limb. Both electrodes
were connected to the pulse generator, after which 1 test pulse was
applied manually.
Approximately 20 min after the induction of anaesthesia, hind
limb ischemia was induced by placing an orthodontic rubber band
(ORB) around the proximal thigh using a McGivney ligator
applicator. Dark pink discoloration of the ischemic toes and
absence of swelling indicated successful occlusion of arterial and
venous blood flow. After ORB application, the N. ischiadicus was
stimulated electrically with 20 pulses at 10 sec intervals. The
minimal electric current needed for a maximal contraction and the
number of pulses needed to reach exhaustion of the muscle were
determined in a pilot study. Stimulus parameters were controlled
by an S48 stimulator, connected to a SIU5 telefactor stimulus
isolation unit and a constant current unit (all by Grass, Astro-Med,
Rodgau, Germany). Pulses were generated at 0.1 tps train rate,
250 ms train duration, 150 pps stimulus rate, 0.1 ms stimulus
delay and 0.1 ms duration at 150 volt. The constant current unit
was used to adjust the electric current output to 0.9 ampere.
After completion of the stimulation protocol, 99mTc-DA5 or
99mTc-ANXA5 was administered i.v. via the tail vein (200 mg/kg
b.w.; 20 mCi per mouse). Immediately after DA5 or ANXA5
administration, blood circulation was restored by cutting the ORB
(total ischemia time was 5 min). After the desired reperfusion time
Figure 6. Diannexin and annexin A5 share the same target in the muscle after ischemic exercise. (A–B) Uptake of annexin A5 (ANXA5,
panel A) and Diannexin (DA5, panel B, n = 4–8) in control limbs (filled bars) and limbs subjected to ischemic exercise and reperfusion (open bars). (A)
When compared to the control limb, targeting of 99mTc-ANXA5 was increased in hind limb muscle tissue subjected to ischemic exercise and 10, 30, 60
and 120 min of reperfusion. (B) Similarly, 99mTc-DA5 was increased in hind limb muscle tissue subjected to ischemic exercise and 10, 30, 60 and
120 min of reperfusion. Values are means 6 SEM. *P= 0.03 vs. ctrl group (paired t-test); **P,0.001, ***P,0.0001 vs. ctrl group (one-way ANOVA).
n = 3–4 for 10, 30 and 120 min reperfusion and n=7–8 for 60 min reperfusion. (C–D): effect of pre-treatment with unlabeled annexin A5 (ANXA5) on
the targeting of labelled ANXA5 and Diannexin (DA5) to control muscle (filled bars) and ischemically exercised muscle (open bars). 99mTc-ANXA5 (C)
and 99mTc-DA5 (D) target to the hind limb muscle after ischemic exercise and 60min of reperfusion. This targeting was blocked by administration of
450 mg of unlabeled ANXA5 prior to ischemia. In the presence of unlabeled ANXA5, targeting to the ischemic muscle was not significantly different
from control muscle. Values are means 6 SEM. **P,0.001 vs. control muscle; #P,0.05 vs. ischemic muscle - unlabeled ANXA5. n = 3 for ANXA5 pre-
treated mice and n=6–7 for control mice.
doi:10.1371/journal.pone.0024276.g006
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(10, 30, 60 or 120 min), mice were sacrificed by cervical
dislocation, and the 99mTc concentration of the hind limb muscles
was determined in a gamma counter (Wizard, Pharmacia-LKB).
The effect of a preceding injection of unlabeled ANXA5
(450 mg per mouse) was tested in two separate groups of mice
(n = 3 per treatment). The unlabeled ANXA5 was injected i.v. via
the tail vein immediately prior to hind limb occlusion. The rest of
the protocol was as described above.
Renal I/R model
For recovery experiments, ethical guidelines prescribe the use of
analgesia with either non-steroidal anti-inflammatory drugs or
opiates. Since opiates are known to influence IRI signalling,
carprofen (5 mg/kg b.w.) was selected as analgesic in all
experimental and control groups, even though this drug may
possibly have effects on renal function and inflammatory cells.
Carprofen was administered s.c. 30 min prior to surgery. DA5
(200 mg/kg b.w.) or vehicle (physiological salt solution) was
administered i.v. via the tail vein [25,24]. Hereafter, anaesthesia
was induced, the incision site was shaved, iodized and covered
with sterile surgery foil, after which mice were laparotomized. The
jejunum, ileum and cecum were temporarily placed outside the
abdomen, wrapped in gauze and kept moist with physiological salt
solution. For both kidneys, the renal vein and artery were isolated
and clamped for 20 min using non-traumatic microvascular
clamps (S&T, Neuhausen, Switzerland). Time between DA5 or
vehicle administration and clamping was 615 min. Complete
occlusion of blood flow and reperfusion after clamp release were
confirmed visually by swift dis- and re-coloration of the kidney.
After clamp removal, the intestine was placed back, the abdominal
wall and skin were sutured and the animals were allowed to
recover in a clean housing cage. Analgesic (carprofen, 5 mg/kg
b.w.) was administered s.c. 24 h and 48 h post-op. On day 3 or
day 8 post-op, mice were anesthetized with 5% isoflurane in O2/
N2O and sacrificed through exsanguination (8–10 mice per day
per treatment). Sham operated mice (n = 5 per treatment)
underwent all procedures described above, except for clamp
placement, and were sacrificed on day 3 post-op.
Tissue handling and renal histology
Blood samples were collected in EDTA tubes and centrifuged
for 15 min at 3000 g to obtain plasma. Plasma and urine aliquots
were snap frozen in liquid nitrogen and stored at 280uC until
further use. For immunohistochemistry, tissue was embedded in
Tissue-Tek Optimal Cutting Temperature (OCT) compound
(Sakura Finetek, Zoeterwoude, The Netherlands) and snap frozen
in liquid nitrogen. Tissues were stored at 280uC until further use.
For histological studies, tissue was fixed in 4% paraformaldehyde
for at least 24 h.
For light microscopy of the renal cortex, K kidneys were
dehydrated and embedded in paraffin. For damage scoring,
sections of 5 mm were stained with periodic acid-Schiff (PAS). For
each kidney, 4 sections taken at different latitudes were scored for
damage of the renal cortex and averaged. Damage scoring was
performed on a scale from 0 to 5, with 0 signifying no proximal
tubule damaged, and 5 indicating that all tubules were damaged
(see also Figure 1A-D and legend). For leukocyte counting, 5 mm
sections were stained with Leder’s esterase, which stains all
myeloid granulocytes and mast cells. Images of 10 random fields of
the renal cortex were obtained at 400x magnification for each
kidney. Granulocytes were counted in these 10 fields and averaged
for each kidney. For both damage and granulocyte scoring, the
investigator was blinded for the experimental group to which the
mice had been assigned.
Membrane preparation and Western blotting
Total membrane fractions were obtained using a micro-
dismembrator (Sartorius BBI Systems GmbH, Melsungen, Ger-
many), as described previously [39]. Frozen kidneys were
pulverized (2000 rpm, 30 s) and transferred to ice-cold TS buffer
(10 mM Tris-HCl, 250 mM sucrose) including protease inhibitors
(complete Mini, Roche, Mannhein, Germany). From these
suspensions, a supernatant containing the total protein fraction
was prepared through centrifugation (30 min612000 g, 4uC).
Protein concentrations were determined with a standard protein
assay (Biorad, Veenendaal, The Netherlands).
For Western blot analysis, samples were blotted in a blinded
fashion to avoid bias and were therefore randomly distributed over
several blots. Ten ml samples corrected for protein amount were
solubilized in Laemmli sample buffer, heated at 95uC for 5 min,
separated on a 10% polyacrylamide gel, and transferred to a
nitrocellulose membrane using the Iblot system (Invitrogen, Breda,
The Netherlands). Subsequently, the blot was blocked for 60 min
with 5% nonfat dry milk powder in PBS supplemented with 0.1%
Tween 20 (PBS-T), after which the blot was washed three times in
PBS-T. The membrane was incubated overnight at 4uC with the
primary antibodies: RbaH polyclonal KIM-1 (AbD serotec,
Oxford, UK) diluted 1:1000, RaM monoclonal NGAL (Santa
Cruz, Heidelberg, Germany) diluted 1:1000 and MaM b-actin
(Sigma, Zwijndrecht, The Netherlands) diluted 1:100.000. The
blot was washed twice for 20 min with PBS-T, rinsed three times
with PBS and then blocked for 30 min as described above. The
blot was then washed three times for 20 min with PBS-T and
incubated at room temperature for 60 min with secondary
antibodies alexa680-GaRb, alexa680-GaR (both Invitrogen,
Breda, The Netherlands) or alexa800-GaM (Rockland, Gilberts-
ville, PA), diluted 1:5000. Finally, the blot was washed twice for
20 min with PBS-T and rinsed twice in PBS. Proteins were
visualized using the Odyssey Infrared Imaging Scanner (LI-
CORH, Lincoln, NE). Semi-quantitative analyses were performed
by correcting relative fluorescence from the proteins of interest for
housekeeping protein (ß-actin) fluorescence.
RNA isolation and cDNA reaction
RNA isolation and cDNA reaction were performed on K
kidney from each mouse as described previously [39]. RTQ-PCR
was performed in duplicate on approximately 1 ng cDNA, using
the ABI/PRISM 7900HT Gene Expression Micro Fluidic Card
(Applied Biosystems, Foster City, CA) according to the manufac-
turer’s instructions. Primers for KIM-1 (forward 59- GCT-
ATGCTCTCCCTCACGCCA-39 and reverse 59- CTCTTT-
GATGTCACGCACGAT-39) and b-actin (forward 59-CCTCCA-
CTCCTCCAACATCTACA-39 and reverse 59-ACTGTCCTTA-
GGGTAGGGT-39) were developed using the primer express
software (Applied Biosystems, Zwijndrecht, The Netherlands).
cDNA amplification of KIM-1 and b-actin was performed in 2x
SYBR GreenH PCR Master Mix, supplemented with 1.5 ml of
10 mM forward and reverse primer in a total reaction volume of
25 ml. cDNA amplification of NGAL and b-actin was performed
in TaqmanH Universal PCR Master Mix, supplemented with 20x
solution of each primer probe set.
The thermal cycling conditions were 2 min at 50uC and 10 min
at 95uC, followed by 40 cycles of 10 s at 95uC and 1 min at 60uC.
PCR reactions were analyzed using 700 System Sequence
Detection Software (version 1.2.3, Applied Biosystems).
Data analysis
Data are given as means 6 SEM. Number of animals used is
given in the figure legends. Mean values were considered to be
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significant when P,0.05 by use of a two-way ANOVA, one-way
ANOVA or Student’s t-test where applicable. Software used for
statistical analysis was Graphpad PrismH (version 5.02 for
Windows; Graphpad Software, San Diego, CA).
Supporting Information
Figure S1 Whole body scintigraphy and blood elimina-
tion of i.v. 99mTc-Annexin A5 (ANXA5; top panel) or
99mTc-Diannexin (DA5; bottom panel), over a time
course of 2 h. (A) Accumulation of ANXA5 in kidney and loss of
signal from the peripheral circulation occur rapidly after injection.
Excretion of ANXA5 via the urine is evident 30 to 120 min after
injection (arrows indicate bladder). (B) Accumulation of DA5 is
detected in kidney, liver and spleen immediately after injection.
Note the prolonged activity in the peripheral circulation,
indicating the prolonged half-life of DA5. (C, D) Elimination
curves of ANXA5 (C) and DA5 (D) as calculated from blood
99mTc activity, 10 to 120 min post-injection. n= 3 mice per
treatment.
(PDF)
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